Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines,
RSV season is upon us, which means thousands of children under five years of age and hundreds of thousands of adults will be ...
Hosted on MSN2d
Year in Review: RSVThis year's headlines on respiratory syncytial virus (RSV) focused largely on the relatively new vaccines -- including a ...
The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...
Glamour on MSN8d
RSV Symptoms: Here’s How the Virus Shows Up Differently in Babies, Adults, and SeniorsJust like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...
Dr. Kerry-Anne Perkins, a new mom and board-certified OB-GYN shares what parents need to know about RSV and more.
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Residents of Australia’s northern regions have sweltered as a heatwave has continued through the weekend, and is expected to ...
The Royal Australian College of GPs (RACGP) has lauded the Federal Government's announcement of $174.5 million to provide free RSV vaccination during ...
Moderna (MRNA) announced Health Canada has approved mRESVIA for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 60 years of ...
Hosted on MSN20h
'We are becoming overwhelmed': North Texas hospitals see sharp increase in RSV casesCook Children's Medical Center doctors on Friday warned of the rise in cases of Respiratory Syncytial Virus, or RSV, as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback